US panel rejects psychedelic drug MDMA as a PTSD treatment in possible setback for advocates
A first-of-a-kind proposal to begin using the mind-altering drug MDMA as a treatment for post-traumatic stress disorder (PTSD) in the US was criticised on Tuesday by a panel of experts. In what could be a major setback to advocates hoping to win federal approval for medical psychedelics, a panel of advisers to the Food and Drug Administration (FDA) voted 10-1 against the overall benefits of MDMA when used to treat PTSD. “It seems like there are so many problems with the data - each one alone might be OK, but when you pile them on top of each other … there’s just a lot of questions I would have...